Clinical Trial

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-13; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-04-01
Trial Details
NCT Number NCT06183307
Lead Sponsor Universidade Federal Fluminense
Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Conditions Cardiovascular Diseases, Dyslipidemias, Inflammation
Enrollment 48 participants
Start Date 2024-08-03
Primary Completion 2026-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-14